HC Wainwright Issues Positive Forecast for ZNTL Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Equities research analysts at HC Wainwright raised their Q1 2025 earnings per share (EPS) estimates for Zentalis Pharmaceuticals in a report issued on Wednesday, January 29th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($0.41) for the quarter, up from their previous forecast of ($0.65). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Zentalis Pharmaceuticals’ Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($1.65) EPS, FY2026 earnings at ($2.03) EPS, FY2027 earnings at ($2.00) EPS and FY2028 earnings at ($1.42) EPS.

Several other equities analysts have also recently issued reports on ZNTL. Guggenheim cut their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. Wells Fargo & Company dropped their price objective on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 30th. Wedbush reissued a “neutral” rating and issued a $4.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday, January 24th. Finally, UBS Group lowered their target price on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $8.24.

Zentalis Pharmaceuticals Stock Down 3.0 %

NASDAQ:ZNTL opened at $1.63 on Monday. Zentalis Pharmaceuticals has a 52 week low of $1.61 and a 52 week high of $18.07. The stock has a market cap of $116.16 million, a price-to-earnings ratio of -0.65 and a beta of 1.86. The company’s 50 day moving average price is $2.87 and its 200-day moving average price is $3.23.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.36.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. American Century Companies Inc. bought a new position in Zentalis Pharmaceuticals in the 2nd quarter worth $95,000. Bank of Montreal Can purchased a new stake in Zentalis Pharmaceuticals in the second quarter worth about $402,000. Squarepoint Ops LLC raised its stake in shares of Zentalis Pharmaceuticals by 543.8% in the second quarter. Squarepoint Ops LLC now owns 148,755 shares of the company’s stock worth $608,000 after buying an additional 125,649 shares during the period. Algert Global LLC bought a new position in shares of Zentalis Pharmaceuticals in the second quarter worth about $78,000. Finally, SG Americas Securities LLC lifted its position in shares of Zentalis Pharmaceuticals by 84.8% during the 3rd quarter. SG Americas Securities LLC now owns 26,149 shares of the company’s stock valued at $96,000 after buying an additional 11,997 shares in the last quarter.

Insiders Place Their Bets

In other Zentalis Pharmaceuticals news, Director Jan Skvarka purchased 60,000 shares of the firm’s stock in a transaction on Friday, January 31st. The shares were acquired at an average cost of $1.72 per share, for a total transaction of $103,200.00. Following the completion of the transaction, the director now owns 149,551 shares of the company’s stock, valued at approximately $257,227.72. The trade was a 67.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 3.60% of the company’s stock.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.